Navigation Links
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Date:5/8/2008

uded dizziness and nausea.

About Diabetic Neuropathic Pain

Diabetic neuropathic pain is a painful and potentially debilitating complication of diabetes often characterized by a stabbing or burning sensation in the legs, feet and/or hands. It is caused by damage or dysfunction to the peripheral nervous system as a result of diabetes or impaired glucose tolerance. Diabetic neuropathic pain often substantially interferes with sleep, recreational activities, mobility, and normal work and social activities, and many patients with the condition experience a significantly reduced quality of life. With the overall prevalence of diabetes in the U.S. estimated at 20.8 million people, it is thought that as many as 7.7 million have some degree of diabetic neuropathic pain.

About UCB

UCB (Euronext: UCB) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Georgia. For more information about UCB, visit http://www.ucb-group.com

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
2. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
3. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
4. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
5. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
8. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...of Phase 1 Clinical Data of MDX-1100 at Digestive ..., PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ ...that it has initiated the Phase 2 clinical,develop... antibody that,targets CXCL10 (also known as IP-10...itis (RA). MDX-1100 could potentially treat UC and...
(Date:5/9/2008)...Thailand, May 9 /PRNewswire-USNewswire/ -- An emer...he Protection of Animals (WSPA),is on stand-by in ...k,Myanmar to assess and then relieve the suffering...nd on for food and their livelihoods., WSPA is ...ure,Organization of the United Nations (FAO) while...
(Date:5/9/2008)..., May 9 /- Ardea Bioscience... discovery and development of,small- molecule ther...ammatory diseases, including gout, today announced...President, Finance and Operations and Chief,Financ... from our board of,directors shortly thereafter. T...
(Date:5/8/2008)...y 8 /- Globus Medical, Inc., the larg...the world and a recognized,leader in motion preser...of,enrollment in its SECURE(R)-C Cervical Artifici...ned to mimic the normal motion of the spine in,ord...ternative to fusion in,the treatment of symptomati...
Breaking Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4Animals That Cyclone Survivors Depend on Need Help Now 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2High Meat Consumption Linked to Heightened Cancer Risk 8025 1High Meat Consumption Linked to Heightened Cancer Risk 8025 2High Meat Consumption Linked to Heightened Cancer Risk 8025 3High Meat Consumption Linked to Heightened Cancer Risk 8025 4Panomics Inc 3A Recipient of the Frost 26 Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 8020 1Panomics Inc 3A Recipient of the Frost 26 Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 8020 2Panomics Inc 3A Recipient of the Frost 26 Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 8020 3UT Southwestern 3A Patients with mild Cushing syndrome may benefit from adrenalectomy 8017 1UT Southwestern 3A Patients with mild Cushing syndrome may benefit from adrenalectomy 8017 2UT Southwestern 3A Patients with mild Cushing syndrome may benefit from adrenalectomy 8017 3News from the American Heart Association 1035 1News from the American Heart Association 1035 2News from the American Heart Association 1035 3News from the American Heart Association 1035 4News from the American Heart Association 1035 5
...AM, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Interle...t the University of,California San Diego today rep... meeting that associations between coronary artery...PL) and Lp(a),levels appear to be dependent on pro... genes., In a presentation titled "The Influence o...
...ETON, N.J.--(BUSINESS WIRE)--Mar 29, 2007 - Cytoge...coming presentation,of preclinical data at the 200...ancer Research (AACR) taking place in Los Angeles,...are based on,preclinical studies that validate nov...bodied in the Company,s proprietary,Abtides(TM) (A...
Other Medicine Technology:ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 2ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 3Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 2Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 3Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 4
(Date:5/12/2008)...n-compliance with California Environmental ...S, May 12 /PRNewswire-USNewswire/ -- Providence Ho...ith the planned expansion of its,Holy Cross Medica...Knew,Jr. has upheld charges that the approval pro...ceremony held today appears to be an attempt to cr...
(Date:5/12/2008)...e-FirstCall/ - Med-Emerg International Inc.,(OTCBB...uing operations,for the three months ended March ...n for the same period in 2007 (all amounts are $US...iod, earnings before,depreciation, amortization, i...a loss of ($106K) in 2007. The improvement in EBIT...
(Date:5/12/2008)...RNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT) W...ration") announced,that the Toronto Stock Exchange...viewing the eligibility for continued listing on t...ctions 709 and 710(a) of the TSX Company,Manual. T...ition and,operating results, more specifically whe...
(Date:5/12/2008).../PRNewswire/ -- Keck Graduate Institute (KGI),toda...remony will feature,the graduation of KGI,s first ...d the unveiling of KGI,s first donated artwork., ...nt in becoming the,first graduate of our new PhD p...president for academic affairs, dean of faculty an...
Breaking Medicine News(10 mins):Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2
...st that can detect non-small cell lung cancer (NSC... University of Kentucky. The test is highly accura...several years before they are identified by advanc...ided to partner with 20/20 GeneSystems Inc for the...
...vices in Australia’s Townsville will be revolution...given to the James Cook University (JCU).// A rura...bbott, the Health Minister, at JCU. The University...students to study in Atherton, Cairns, and Mackay....
...ords Science and Technology Committee has issued a...ritain, there would be a severe shortage of food. ...up efforts to collaborate on an international leve...re alternative plans to combat an epidemic should ...
...ated to Food science and consumer acceptance in No...s react differently then do experts to cheese.// T...nsumers were compared with expert dairy assessors....eaction of consumers and quality scores by experts...
Other Medicine News:
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
Medicine Products: